30th Oct 2015 14:32
Silence Therapeutics plc
("Silence" or "the Company")
Licensee's drug to commence Phase 2 and Phase 3 trials
Further validation of our proprietary technology
The Company is aware of certain information released yesterday by SBI Holdings Inc., the parent of Quark Pharmaceuticals, Inc. ("Quark"), a wholly owned subsidiary of SBI Biotech Co., Ltd, which indicates that Quark is to begin, in December 2015, a Phase 3 trial in renal delayed graft function using its QPI-1002 drug. Quark will also begin a Phase 2 trial at the same time using QPI-1002 for acute kidney injury. Novartis has an option to license the drug in both indications. Silence may receive potential milestone payments but has no future obligations in regard to these programmes. This is further validation of our proprietary technology which underpins Silence's own pipeline.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer Timothy Freeborn, Chief Financial Officer | Tel: +44 (0)20 3457 6900
|
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel | Tel: +44 (0)20 7523 8350
|
Peel Hunt LLP (Joint Broker) James Steel/Dr Tom Burt/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert | Tel: +44 (0) 20 3727 1000
|
Notes to Editors
About Silence Therapeutics plc
Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.
We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.
Related Shares:
SLN.L